Advances Bring New Immunotherapy and Targeted Therapy Options for Non-Muscle Invasive Bladder Cancer – Kriti Mittal & Guru Sonpavde
Kriti Mittal and Guru Sonpavde discuss advancements in the treatment of non-muscle invasive bladder cancer. Dr. Mittal highlights the FDA’s 2020 approval of pembrolizumab for high-risk, BCG-unresponsive cases, based on the KEYNOTE-057 study. This study demonstrated a notable clinical response at three and twelve months. Atezolizumab, although showing some response, didn’t meet its threshold in a…